Knockdown or pharmacological inhibition of FASN selectively induces cell death of cancer cells and a reduction in tumor volume in xenograft mouse models with only a minimal effect on normal cells, indicating that FASN is a promising target for cancer treatment with the potential for a large therapeutic index (reviewed in [4]). The gene discussed is FASN; the disease is cancer.